Biomarker-confirmed suboptimal adherence to isoniazid preventive therapy among children with HIV in western Kenya
- PMID: 37773037
- PMCID: PMC10840836
- DOI: 10.1097/QAD.0000000000003719
Biomarker-confirmed suboptimal adherence to isoniazid preventive therapy among children with HIV in western Kenya
Abstract
Objectives: The aim of this study was to assess the level and correlates of biomarker-confirmed adherence to isoniazid (INH) preventive therapy (IPT) among children with HIV (CLHIV).
Design: This prospective cohort study assessed adherence among CLHIV on IPT in public sector HIV clinics from 2019 through 2020.
Methods: Adherence was assessed by pill counts or caregiver or self-reports, and urine biomarkers (in-house dipstick and Isoscreen). Both urine biomarker tests detect INH metabolites within 48 h of ingestion. Consistent adherence was defined as having positive results on either biomarker at all visits. Correlates of biomarker-confirmed nonadherence at each visit were evaluated using generalized estimating equations. The in-house dipstick was validated using Isoscreen as the reference.
Results: Among 97 CLHIV on IPT with adherence assessments, median age was 10 years (IQR 7-13). All were on ART at IPT initiation (median duration 46 months [IQR 4-89]); 81% were virally suppressed (<1000 copies/ml). At all visits, 59% ( n = 57) of CLHIV reported taking at least 80% of their doses, while 39% ( n = 38) had biomarker-confirmed adherence. Viral nonsuppression (adjusted risk ratio [aRR] = 1.65; 95% confidence interval [95% CI] 1.09-2.49) and the sixth month of IPT use (aRR = 2.49; 95% CI 1.34-4.65) were independent correlates of biomarker-confirmed nonadherence at each visit. Sensitivity and specificity of the in-house dipstick were 98.1% ( 94.7 - 99.6%) and 94.7% ( 88.1 - 98.3%) , respectively, versus Isoscreen.
Conclusion: Biomarker-confirmed adherence to IPT was sub-optimal and was associated with viral nonsuppression and duration of IPT. Urine dipstick testing may be useful in assessing adherence to IPT in clinical care.
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
References
-
- Chintu C, Mudenda V, Lucas S, Nunn A, Lishimpi K, Maswahu D, et al. Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study. Lancet. 2002;360(9338):985–90. - PubMed
-
- Swaminathan S, Rekha B. Pediatric tuberculosis: global overview and challenges. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2010;50.Suppl 3: S184–94. - PubMed
-
- Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Obihara CC, Starke JJ, et al. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2004;8(4):392–402. - PubMed
-
- Nelson LJ, Wells CD. Global epidemiology of childhood tuberculosis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2004;8(5):636–47. - PubMed
-
- Charles MK, Lindegren ML, Wester CW, Blevins M, Sterling TR, Dung NT, et al. Implementation of tuberculosis intensive case finding, isoniazid preventive therapy, and infection control (“ Three I’s”) and HIV-Tuberculosis service integration in lower income countries. PloS one. 2016;11(4):e0153243. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
